Morgan Stanley Immuneering Corp Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Immuneering Corp stock. As of the latest transaction made, Morgan Stanley holds 201,094 shares of IMRX stock, worth $1.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

201,094

Previous 467,226 56.96%

Holding current value

$1.27 Million

Previous $710,000 4.65%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$1.1 - $3.66 $292,745 - $974,043	-266,132 Reduced 56.96%	201,094 $677,000
Q1 2025 May 15, 2025	BUY	$1.46 - $2.36 $19,163 - $30,977	13,126 Added 2.89%	467,226 $710,000
Q4 2024 Feb 14, 2025	BUY	$1.62 - $2.47 $7,758 - $11,828	4,789 Added 1.07%	454,100 $999,000
Q3 2024 May 14, 2025	BUY	$1.03 - $3.21 $415,356 - $1.29 Million	403,259 Added 875.66%	449,311 $1.12 Million
Q3 2024 Nov 14, 2024	BUY	$1.03 - $3.21 $415,356 - $1.29 Million	403,259 Added 875.66%	449,311 $1.12 Million
Q2 2024 May 14, 2025	SELL	$1.28 - $2.75 $522,301 - $1.12 Million	-408,048 Reduced 89.86%	46,052 $58,000
Q2 2024 Oct 17, 2024	BUY	$1.28 - $2.75 $554 - $1,190	433 Added 0.95%	46,052 $58,000
Q2 2024 Aug 14, 2024	BUY	$1.28 - $2.75 $554 - $1,190	433 Added 0.95%	46,052 $58,000
Q1 2024 Oct 17, 2024	SELL	$1.91 - $7.32 $827 - $3,169	-433 Reduced 0.94%	45,619 $131,000
Q1 2024 Aug 16, 2024	SELL	$1.91 - $7.32 $20,110 - $77,072	-10,529 Reduced 18.75%	45,619 $131,000
Q1 2024 May 15, 2024	SELL	$1.91 - $7.32 $20,110 - $77,072	-10,529 Reduced 18.75%	45,619 $131,000
Q4 2023 Aug 16, 2024	BUY	$4.84 - $8.44 $48,864 - $85,210	10,096 Added 21.92%	56,148 $412,000
Q4 2023 Feb 13, 2024	BUY	$4.84 - $8.44 $168,746 - $294,260	34,865 Added 163.82%	56,148 $412,000
Q3 2023 Nov 15, 2023	SELL	$7.21 - $10.68 $31,666 - $46,906	-4,392 Reduced 17.11%	21,283 $163,000
Q2 2023 Aug 14, 2023	SELL	$6.49 - $13.36 $12,824 - $26,399	-1,976 Reduced 7.15%	25,675 $260,000
Q1 2023 May 15, 2023	SELL	$3.78 - $10.38 $67,151 - $184,400	-17,765 Reduced 39.12%	27,651 $268,000
Q4 2022 Feb 14, 2023	BUY	$4.09 - $15.0 $137,698 - $505,005	33,667 Added 286.55%	45,416 $220,000
Q3 2022 Nov 14, 2022	SELL	$5.0 - $14.32 $32,690 - $93,624	-6,538 Reduced 35.75%	11,749 $168,000
Q2 2022 Oct 27, 2022	SELL	$3.89 - $7.81 $532 - $1,069	-137 Reduced 0.74%	18,287 $98,000
Q2 2022 Aug 15, 2022	SELL	$3.89 - $7.81 $532 - $1,069	-137 Reduced 0.74%	18,287 $98,000
Q1 2022 Oct 27, 2022	BUY	$6.47 - $16.99 $886 - $2,327	137 Added 0.75%	18,424 $119,000
Q1 2022 May 13, 2022	BUY	$6.47 - $16.99 $50,381 - $132,301	7,787 Added 73.21%	18,424 $119,000
Q4 2021 Feb 14, 2022	BUY	$16.12 - $31.02 $63,335 - $121,877	3,929 Added 58.57%	10,637 $172,000
Q3 2021 Nov 15, 2021	BUY	$17.0 - $32.84 $114,036 - $220,290	6,708 New	6,708 $178,000

Others Institutions Holding IMRX

# of Institutions

Shares Held

3.78M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $166M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account